Sprycel Market Report 2026

Sprycel Market Overview

• Sprycel market size has reached to $2.15 billion in 2025 • Expected to grow to $2.65 billion in 2030 at a compound annual growth rate (CAGR) of 4.3% • Growth Driver: Surge In Leukemia Prevalence Fueling The Growth Of The Market Due To Rising Diagnoses, Particularly Among The Aging Population • Market Trend: Generic Versions Of Sprycel Gain Traction With Apotex's Launch Of Dasatinib Tablets-global-market-report" target="_blank">Tablets • Asia-Pacific was the largest region in 2025 and North America is the fastest growing region.

What Is Covered Under Sprycel Market?

Sprycel is a prescription medication primarily used to treat positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) by targeting specific proteins involved in the growth of cancer cells. It helps prevent the uncontrolled proliferation of leukemia cells, offering a targeted approach to treatment for patients who are resistant to or intolerant of other therapies. The main types of indications in sprycel are chronic myeloid leukemia and acute lymphoblastic leukemia. Chronic myeloid leukemia (CML) is a slow-progressing cancer of the bone marrow and blood caused by a genetic mutation known as the Philadelphia chromosome. It includes various dosage forms such as tablets, oral suspension, distributed through hospitals and clinics, retail pharmacies, online pharmacies, and specialty pharmacies.

What Is The Sprycel Market Growth Forecast?

The sprycel market size is expected to see steady growth in the next few years. It will grow to $2.65 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to growth in precision oncology, personalized cancer treatment, expansion of specialty care, oncology drug innovation, improved survival rates. Major trends in the forecast period include continued use of targeted leukemia therapies, rising use in drug-resistant cml, expansion of precision oncology treatments, growth of specialty oncology pharmacies, focus on long-term disease management.

What Are The Drivers Of The Sprycel Market?

The increasing prevalence of leukemia is expected to propel the growth of the sprycel market going forward. Leukemia is a cancer of the blood and bone marrow characterized by the excessive production of abnormal white blood cells. The rising prevalence of leukemia can be largely attributed to the aging population, as older individuals are more prone to developing the disease, leading to an increase in diagnoses. Sprycel (dasatinib) is useful for treating certain types of leukemia, such as Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), by inhibiting the BCR-ABL protein that drives cancer cell growth. For instance, according to the American Cancer Society (ACS), a US-based nonprofit health organization dedicated to eliminating cancer as a significant health problem, about 59,610 people were diagnosed with leukemia in 2023, with approximately 23,940 deaths. Therefore, the increasing prevalence of leukemia is driving the growth of the sprycel industry. The increasing healthcare expenditure is expected to propel the growth of the sprycel market going forward. Healthcare expenditure refers to the total amount of money spent on healthcare services and products within a specific region or country over a given period. Healthcare expenditure is rising as advancements in medical technology lead to the adoption of expensive diagnostic tools and treatments that improve outcomes but significantly increase costs. Healthcare expenditure supports wider access to innovative cancer treatments such as sprycel by enabling hospitals and health systems to invest in advanced oncology therapies. For instance, in April 2025, according to the Office for National Statistics, a UK-based government department, total healthcare spending increased by 6.5% in nominal terms from 2023 to 2024, slightly up from the 6.3% growth recorded in 2023. Therefore, the increasing healthcare expenditure is driving the growth of the sprycel industry.

Key Players In The Global Sprycel Market

Major companies operating in the sprycel market are Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co. Ltd., Beacon Pharmaceuticals Limited, Panacea Biotec Limited, Apotex Corp., Hubei Haosun Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Lupin Limited, Zydus Lifesciences Limited, Biocon Limited, Zentiva k.s., Alembic Pharmaceuticals Limited, Granules India Limited, Natco Pharma Limited, Shilpa Medicare Limited, Prasco Laboratories, Stason Pharmaceuticals Inc., HRV Global Life Sciences Pvt. Ltd., Sichuan Elixir Pharmaceutical Co. Ltd., Gonane Pharma Limited

Global Sprycel Market Trends and Insights

Major companies operating in the sprycel market are focusing on developing a generic version of sprycel to capitalize on the impending loss of exclusivity and address the growing demand for cost-effective cancer treatments. The generic version of Sprycel refers to dasatinib-based medications produced by other companies after the expiration of the original patent, offering the same therapeutic effects at a lower price. For instance, in September 2024, Apotex Corp., a Canada-based pharmaceutical company, launched dasatinib tablets, a generic version of Sprycel, a kinase inhibitor used to treat specific types of leukemia. Dasatinib is a kinase inhibitor used to treat certain types of leukemia in adults and children aged one year and older, including Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), especially in cases where prior treatments were ineffective or not tolerated. The product is designed to meet high-quality standards-being latex-free, sugar-free, dye-free, alcohol-free, and preservative-free and is available in bottles of 30 or 60 tablets depending on the strength.

What Defines the Sprycel Market?

The sprycel market consists of sales of products including film-coated tablets, powder for oral suspension, blister packaging, pediatric dosing packs, and flavoring agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sprycel Market Report 2026?

The sprycel market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sprycel industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.